Btw @friendlydwarves, fwiw, in 2017 ACR wrote down its Axiron IP to the tune of $10.7m. Ex this, the business would have made a net after-tax profit of $11.8m. Also in that year the business generated FCF of $4.7m. This was low due to a large tax payment in that year amounting to $6.3m - which did not match the actual tax expense for that year. The FCF before tax was $11m which well matches the P&L PBT (before IP impairments), which was $12m.
Ann: Acrux's fifth generic dossier accepted by FDA for review, page-21
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40561 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 17257 | 1 |
View Market Depth
| Last trade - 10.00am 14/10/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable